AAA

Affinity Asset Advisors Portfolio holdings

AUM $676M
This Quarter Return
-3.67%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$639M
AUM Growth
+$639M
Cap. Flow
+$95.5M
Cap. Flow %
14.95%
Top 10 Hldgs %
49.57%
Holding
109
New
20
Increased
27
Reduced
17
Closed
13

Top Buys

1
SPY icon
SPDR S&P 500 ETF Trust
SPY
$16.8M
2
TVTX icon
Travere Therapeutics
TVTX
$15.6M
3
PTGX icon
Protagonist Therapeutics
PTGX
$13.1M
4
NUVL icon
Nuvalent
NUVL
$12.4M
5
MLYS icon
Mineralys Therapeutics
MLYS
$11.9M

Top Sells

1
ARVN icon
Arvinas
ARVN
$12.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
$10.3M
3
SLNO icon
Soleno Therapeutics
SLNO
$5.72M
4
ARWR icon
Arrowhead Research
ARWR
$5.64M
5
SYRE icon
Spyre Therapeutics
SYRE
$5.53M

Sector Composition

1 Healthcare 90.82%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
QTTB icon
76
Q32 Bio
QTTB
$20.9M
$45.8K ﹤0.01%
27,777
– –
RCKTW icon
77
Rocket Pharmaceuticals, Inc. Warrant
RCKTW
$4.17M
$3.53K ﹤0.01%
75,000
– –
IMTXW
78
DELISTED
Immatics N.V. Warrants
IMTXW
$2.96K ﹤0.01%
187,204
– –
NARI
79
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-25,000
Closed -$1.28M
SYRS
80
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-150,000
Closed -$34.5K
TECX
81
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
– –
-58,331
Closed -$2.69M
BBOT
82
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
– –
-250,000
Closed -$2.63M
XBI icon
83
SPDR S&P Biotech ETF
XBI
$5.29B
– –
0
– –
TRML icon
84
Tourmaline Bio
TRML
$645M
– –
0
– –
SVRA icon
85
Savara
SVRA
$591M
– –
-410,586
Closed -$1.26M
SAVA icon
86
Cassava Sciences
SAVA
$107M
– –
0
– –
RAPT icon
87
RAPT Therapeutics
RAPT
$187M
– –
-1,000,000
Closed -$1.58M
NMRA icon
88
Neumora Therapeutics
NMRA
$283M
– –
0
– –
MESO
89
Mesoblast
MESO
$1.65B
– –
0
– –
KZR icon
90
Kezar Life Sciences
KZR
$28.5M
– –
-142,316
Closed -$956K
IWM icon
91
iShares Russell 2000 ETF
IWM
$66.6B
– –
0
– –
IBRX icon
92
ImmunityBio
IBRX
$2.24B
– –
0
– –
GALT icon
93
Galectin Therapeutics
GALT
$288M
– –
0
– –
EXEL icon
94
Exelixis
EXEL
$9.95B
– –
0
– –
EWTX icon
95
Edgewise Therapeutics
EWTX
$1.54B
– –
0
– –
CORT icon
96
Corcept Therapeutics
CORT
$7.52B
– –
0
– –
CMPS
97
Compass Pathways
CMPS
$452M
– –
-850,512
Closed -$3.21M
CLDX icon
98
Celldex Therapeutics
CLDX
$1.57B
– –
-9,992
Closed -$252K
CGON icon
99
CG Oncology
CGON
$2.19B
– –
-100,000
Closed -$2.87M
BMEA icon
100
Biomea Fusion
BMEA
$114M
– –
0
– –
1 2 3
4
5